Sanofi-Synthelabo, a French Pharmaceutical Company created Rimonabant (Acomplia and possibly Zimulti) which is a new drug treatment for obesity and possibly other ailments.
This diet pill was officially approved in Britain on June 28th 2006, which could lead the way to having the FDA approve it in the United States by mid summer, 2007.But no guarantees, The FDA has strick policies regarding new medications on the market. Acomplia (Rimonabant or Zimulti) diet pills offer hope for obese individuals, especially where other treatments had little affect or the side effects where too much to handle. This medication (as any) obviously does not come without some potential side effects.
Rimonabant works differently than other weight-loss pills, and has other potential benefits. Studies also show that it increases levels of HDL (good cholesterol) while at the same time reducing LDL (bad cholesterol). It could also possibly be used for smoking cessation, although not officially approved for that purpose (yet). Basically, Rimonabant suppresses ones appetite.It works by blocking a cellular receptor in the endocannabinoid system of the brain, believed to influence the regulation of body weight, glucose, and fat metabolism. In doing so it is believed that this regulation then reduces the craving to eat more.

Clinical Studies have shown that 33% of people taking Rimonabant lost 10% of body weight and kept their weight down for two years which is extremely newsworthy as no other diet drug has accomplished this for so long a period.
It also holds huge potential for the people wanting to kick the smoking habit and ‘may’ help curb other substance addictions such as cocaine, marijuana, and alcohol.
While FDA held up Sanofi’s diet drug Rimonabant(Acomplia/Zimulti),the Merck’s MK-0364(Taranbant) is currently in phase-3 which is as effective for weight loss as rimonabant having some side effects.
The interim results of phase-3 trial of Taranabant have not been reported by the Merck.These results could be different from the anecdotal report. In the trial it was found that the weight loss pill was well tolerated in extensive phase-2.The Merck is looking forward FDA approval for it next year.
Pfizer, which also contains CB-1 receptor antagonist in phase-3 trials has not moved forward with a name which is known as CP-945598.
In June, 2007 there will be a meeting of FDA advisory panel on rimonabant about the safety issues of drugs which affect receptors in the brain.If you are interested in trying this diet pill i recommend the original site from where you can buy rimonabant and many other weight loss pills.